TH Theratechnologies Inc.

Theratechnologies to Announce Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update

Theratechnologies to Announce Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update

MONTREAL, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (“Theratechnologies”), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its fourth quarter and full year fiscal 2022 ended November 30, on Tuesday, February 28, 2023.

The conference call will be held at 8:30 a.m. (ET) on February 28, 2023, to discuss the results and recent business updates. The call will be hosted by Paul Lévesque, President and Chief Executive Officer. Joining Mr. Lévesque on the call will be other members of the management team, including Chief Financial Officer Philippe Dubuc, Chief Medical Officer Christian Marsolais, and Chief Commercial Officer John Leasure, who will be available to answer questions from participants following prepared remarks.

Participants are encouraged to join the call at least ten minutes in advance to secure access.

Conference call dial-in and replay information is below:

CONFERENCE CALL INFORMATION
Conference Call Date:February 28, 2023
Conference Call Time:8:30 AM ET
North America Dial-in:1- 877-513-4119
International Dial-in:1- 412-902-6615
Access Code:2102918
CONFERENCE CALL REPLAY
North America Dial-in:1- 877-344-7529
International Dial-in:1- 412-317-0088
Replay Access Code: 3648244
Replay End DateMarch 07, 2023



The live conference call will be accessible via webcast at:

About Theratechnologies

Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Further information about Theratechnologies is available on the Company's website at , on SEDAR at and on EDGAR at .

Investor Inquiries:

Elif McDonald

Senior Director, Investor Relations



1-438-315-8563

Media Inquiries:

Julie Schneiderman

Senior Director, Communications and Corporate Affaires



1 514 336-7800



EN
14/02/2023

Underlying

THTheratechnologies Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Theratechnologies Inc.

 PRESS RELEASE
Free
TH Theratechnologi...

Theratechnologies Reports on its Annual Meeting of Shareholders

Theratechnologies Reports on its Annual Meeting of Shareholders MONTREAL, May 29, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, reported the voting results from its annual meeting of shareholders held today in a virtual-only setting. Shareholders proceeded to elect the below candidates to the Company’s Board of Directors for a one-year term, appointed KPMG LLP as the Company’s auditors for the current fiscal year and approved the adoption of an omnibus long-term incentive plan...

May 29, 2025 1 EN
 PRESS RELEASE
Free
TH Theratechnologi...

Theratechnologies rend compte de son assemblée annuelle des actionnair...

Theratechnologies rend compte de son assemblée annuelle des actionnaires MONTRÉAL, 29 mai 2025 (GLOBE NEWSWIRE) -- Theratechnologies inc. (« Theratechnologies » ou la « Société ») (TSX : TH) (NASDAQ : THTX), une société biopharmaceutique au stade commercial, a rapporté les résultats du vote lors de son assemblée annuelle des actionnaires qui a eu lieu aujourd’hui en mode virtuel uniquement. Les actionnaires ont voté pour les divers candidats mentionnés ci-dessous en vue de leur élection au conseil d’administration de la Société pour un mandat d’un an, ont nommé KPMG s.r.l./S.E.N.C.R.L. à...

May 29, 2025 1 EN
 PRESS RELEASE
Free
TH Theratechnologi...

Theratechnologies Presents Novel Data at ACTHIV 2025 Underscoring Impo...

Theratechnologies Presents Novel Data at ACTHIV 2025 Underscoring Importance of Managing Excess Visceral Abdominal Fat (EVAF) in People with HIV VAMOS analysis highlights link between EVAF and reduced muscle quality Case series reports success with combination tesamorelin/GLP-1 receptor agonist therapy MONTREAL, May 02, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced two poster presentations at the 19th Annual American Conference for the Treatment of HIV (ACTHI...

May 2, 2025 1 EN
 PRESS RELEASE
Free
TH Theratechnologi...

Theratechnologies présente à la conférence ACTHIV 2025 de nouvelles do...

Theratechnologies présente à la conférence ACTHIV 2025 de nouvelles données soulignant l’importance de prendre en charge l’excès de graisse viscérale abdominale chez les personnes vivant avec le VIH L’analyse réalisée dans le cadre de l’étude VAMOS met en évidence le lien entre l’excès de graisse viscérale abdominale et la diminution de la qualité musculaire Selon ce qu’on rapporte dans la série de cas, l’association de la tésamoréline à un agoniste des récepteurs du GLP-1 fonctionne. MONTRÉAL, 02 mai 2025 (GLOBE NEWSWIRE) -- Theratechnologies inc. (« Theratechnologies » ou la « Sociét...

May 2, 2025 1 EN
 PRESS RELEASE
Free
TH Theratechnologi...

Theratechnologies Provides Update on Sale Process

Theratechnologies Provides Update on Sale Process MONTREAL, April 15, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced that following careful consideration of the current circumstances, including the publicly announced proposal from Future Pak, the Board of Directors of the Company (the “Board”) has decided to further evaluate the potential sale of the Company through an open and non-exclusive process. In connection with this determination, the Board has authorized...

April 15, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch